News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
4,508 Results
Type
Article (421)
Company Profile (2)
Press Release (4085)
Section
Business (1595)
Career Advice (8)
Deals (245)
Drug Delivery (4)
Drug Development (813)
FDA (137)
Job Trends (189)
News (2775)
Policy (268)
Tag
Academia (14)
Alliances (459)
Alzheimer's disease (1)
Antibody-drug conjugate (ADC) (14)
Approvals (140)
Artificial intelligence (4)
Autoimmune disease (2)
Bankruptcy (2)
Best Places to Work (164)
Biotechnology (2)
Bladder cancer (16)
Brain cancer (1)
Breast cancer (1)
Cancer (63)
Career advice (7)
Career pathing (4)
CAR-T (4)
Cell therapy (15)
Clinical research (746)
Collaboration (22)
COVID-19 (5)
CRISPR (1)
C-suite (13)
Cystic fibrosis (1)
Data (45)
Dermatology (3)
Diagnostics (6)
Drug discovery (6)
Drug pricing (6)
Earnings (539)
Events (640)
Executive appointments (11)
FDA (158)
Frontotemporal dementia (2)
Funding (14)
Gene editing (3)
Generative AI (1)
Gene therapy (14)
GLP-1 (6)
Government (33)
Guidances (6)
Healthcare (33)
Indications (1)
Infectious disease (5)
Inflation Reduction Act (3)
Intellectual property (2)
IPO (92)
IRA (4)
Job creations (29)
Job search strategy (3)
JPM (1)
Kidney cancer (1)
Labor market (3)
Layoffs (14)
Leadership (1)
Legal (41)
Lung cancer (3)
Machine learning (1)
Manufacturing (3)
Medical device (2)
Medtech (2)
Mergers & acquisitions (158)
Metabolic disorders (1)
mRNA (1)
Multiple sclerosis (1)
Neurodegenerative disease (1)
Neuroscience (6)
NextGen: Class of 2026 (29)
Non-profit (27)
Opinion (4)
Pancreatic cancer (2)
Partnered (1)
Patents (1)
Patient recruitment (1)
People (577)
Phase 1 (198)
Phase 2 (269)
Phase 3 (358)
Pipeline (58)
Policy (7)
Postmarket research (18)
Preclinical (49)
Prostate cancer (13)
Radiopharmaceuticals (2)
Rare diseases (5)
Real estate (21)
Regulatory (226)
Reports (1)
Research institute (4)
Rett syndrome (2)
Series A (2)
Special edition (1)
Spinal muscular atrophy (7)
Startups (45)
Stomach cancer (2)
The Weekly (2)
Vaccines (2)
Venture capital (2)
Weight loss (1)
Women's health (3)
Date
Last 7 days (3)
Last 30 days (13)
Last 365 days (151)
2026 (37)
2025 (157)
2024 (254)
2023 (353)
2022 (409)
2021 (395)
2020 (404)
2019 (288)
2018 (219)
2017 (212)
2016 (254)
2015 (222)
2014 (165)
2013 (149)
2012 (168)
2011 (202)
2010 (180)
Location
Africa (2)
Arizona (1)
Asia (623)
Australia (14)
California (106)
Canada (11)
China (7)
Europe (454)
Georgia (3)
Illinois (18)
Indiana (2)
Japan (40)
Maryland (2)
Massachusetts (50)
Michigan (1)
New Jersey (20)
New York (29)
Northern California (76)
Ohio (1)
Pennsylvania (6)
South America (5)
Southern California (25)
Tennessee (1)
Texas (3)
United States (241)
Washington D.C. (2)
Washington State (7)
4,508 Results for "astellas".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform
Astellas Pharma and CytomX Therapeutics first partnered up in March 2020. For $80 million upfront, the Japanese pharma gained access to the biotech’s Probody platform to generate masked antibody therapies for cancer.
March 17, 2026
·
2 min read
·
Tristan Manalac
Collaboration
Astellas Bets up to $1.7B for Vir’s ‘Robust Competitor’ in Prostate Cancer
In a Phase 1 study, 82% of patients on VIR-5500 achieved at least a 50% reduction in PSA levels—a result analysts praised as competitive in the prostate cancer space.
February 24, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
·
3 min read
Press Releases
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
February 24, 2026
·
10 min read
Press Releases
Astellas Announces Top Management Personnel Change
September 29, 2025
·
2 min read
Press Releases
Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines
December 11, 2025
·
2 min read
Press Releases
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
December 11, 2025
·
14 min read
Press Releases
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
October 1, 2025
·
7 min read
Press Releases
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
December 5, 2025
·
15 min read
Press Releases
Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
October 14, 2025
·
8 min read
1 of 451
Next
